Astra’s Crestor Fails to Beat Lipitor in Heart Disease Effects - Businessweek
Links shared publicly online about this topic.
- 0total visits
Astra’s Crestor Fails to Beat Lipitor in Heart Disease Effects - Businessweek
View full resource at businessweek.com
Tags: Heart, Heart Disease, Coronary Artery Disease, Cholesterol Medication, Disease and Condition, Lipitor, Crestor, disease
Most Recently Shared on November 24, 2011 at 1:09 am By:
Astra’s Crestor Fails to Beat Lipitor in Heart Disease Effects: AstraZeneca Plc’s Crestor failed to beat Pfizer ... http://t.co/W0xtwPkI
NIH Launches Collaborative Program, Matches Researchers with Compounds to Explore New Treatments | Highlight HEALTH
highlighthealth.com — “Scientists will gain access to select compounds from Pfizer, AstraZeneca and Lilly.” View full resource at highlighthealth.com
Most Recently Shared on May 11, 2012 at 6:38 am By:
Walter Jessen, PhD Pharma, Research, PhD, Active Health Library, and Doctor
NIH Launches Collaborative Program, Matches Researchers with Compounds to Explore New Treatments http://t.co/9VJ9vUnn
NIH Launches Collaborative Program, Matches Researchers with Compounds to Explore New Treatments | Highlight HEALTH
feeds.feedblitz.com — “Scientists will gain access to select compounds from Pfizer, AstraZeneca and Lilly.” View full resource at feeds.feedblitz.com
Most Recently Shared on May 11, 2012 at 12:32 am By:
Inside The Secret World Of Drug Company Rebates - Forbes
forbes.com — “Why AstraZeneca gives insurers 60% discounts on Nexium's list price” View full resource at forbes.com
Most Recently Shared on May 10, 2012 at 2:21 pm By:
Inside The Secret World Of Drug Company Rebates http://t.co/JKk7piAN <--Why $AZN gives 60% of Nexium gross sales back in to insurers.
Antibiotic R&D is in Trouble: Here’s a Fix | Xconomy
xconomy.com — “Bacteria have been on Earth for more than a billion years, evolving in crafty ways to stay alive amid all kinds of threats. Only about 70 years ago, antibiotics” View full resource at xconomy.com
Most Recently Shared on May 7, 2012 at 2:23 pm By:
Luke Timmerman Health Communicator
Free Markets Are Failing Antibiotics: Here’s A Way to Fix Things | Xconomy http://t.co/s7M8437r
NIH, companies aim to teach old drugs new tricks: Associated Press Business News - MSN Money
money.msn.com — “WASHINGTON (AP) - Three pharmaceutical giants are unlocking their freezers to see if government-funded scientists can reinvent some of their old drugs. Pfizer, AstraZeneca and Eli Lilly & Co. entered - MSN Money” View full resource at money.msn.com
Most Recently Shared on May 4, 2012 at 12:51 am By:
Drugs and Devices OW OW Health
Teaching old drugs new tricks: WASHINGTON (AP) - Three pharmaceutical giants are unlocking their freezers to see... http://t.co/usZRSchT
AstraZeneca - NIH launches collaborative program with industry and researchers
astrazeneca.com — “AstraZeneca - NIH launches collaborative program with industry and researchers” View full resource at astrazeneca.com
Most Recently Shared on May 3, 2012 at 6:18 pm By:
AZ #collaboration w/ @MRCcomms to share compounds has received 100+ proposals across 35+ UK academic institutions http://t.co/Omw1j47E
NIH launches collaborative program with industry and researchers to spur therapeutic development, May 3, 2012 News Release - National Institutes of Health (NIH)
nih.gov — “The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH's new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens of their compounds available for this initiative's pilot phase.” View full resource at nih.gov
Most Recently Shared on May 3, 2012 at 2:06 pm By:
NIH launches collaborative program with industry and researchers to spur therapeutic development, M http://t.co/BUfy078r
AstraZeneca - Axerion Therapeutics and AstraZeneca to Develop and Commercialize a Biologic Approach for the Treatment of Alzheimer’s Disease
astrazeneca.com — “AstraZeneca - Axerion Therapeutics and AstraZeneca to Develop and Commercialize a Biologic Approach for the Treatment of Alzheimer’s Disease” View full resource at astrazeneca.com
Most Recently Shared on May 1, 2012 at 3:12 pm By:
Excited to #partner with Axerion Therapeutics to research #biologics for #alzheimer’s disease @medimmune http://t.co/C7yf3NKO
AstraZeneca's new iMed R&D team forges first pact with Axerion - FierceBiotech
fiercebiotech.com — “AstraZeneca's new iMed R&D team forges first pact with Axerion - FierceBiotech” View full resource at fiercebiotech.com
Most Recently Shared on May 1, 2012 at 2:40 pm By:
John Carroll Health Communicator
AZ's new iMed R&D team forges first pact with Axerion - #biotech http://t.co/xuPEWgOH
A.M. Vitals: U.S. Officials Defend Testing Regimen for Mad Cow Disease - Health Blog - WSJ
blogs.wsj.com — “Also: A study shows exposure to violence damages children's DNA; the CDC says a passenger on a flight didn't have monkeypox; and AstraZeneca's CEO will leave as the drug maker reported a drop in profit.” View full resource at blogs.wsj.com
Most Recently Shared on April 27, 2012 at 1:30 pm By:
A.M. Vitals: U.S. Officials Defend Testing Regimen for Mad Cow Disease http://t.co/mjyUPgQU
Sanofi strong in emerging markets as rivals flag | Reuters
uk.reuters.com — “PARIS (Reuters) - French drugmaker Sanofi posted better-than-expected quarterly results, bolstered by strong emerging markets, breaking with a trend of earnings misses by European rivals AstraZeneca and” View full resource at uk.reuters.com
Most Recently Shared on April 27, 2012 at 10:42 am By:
Ben Hirschler Health Communicator
#Sanofi strong in emerging markets in Q1 as rivals #GlaxoxSmithKline and #AstraZeneca flag http://t.co/SkbpGtV6
AstraZeneca CEO quits as drug sales tumble | Reuters
reuters.com — “LONDON (Reuters) - AstraZeneca's chief executive David Brennan is to step down on June 1 in an abrupt exit after six years in the top job, following rising investor discontent at the company's performance.Britain's” View full resource at reuters.com
Most Recently Shared on April 26, 2012 at 10:28 am By:
Ben Hirschler Health Communicator
#AstraZeneca getting pummelled on lousy Q1 results and CEO exit - stock now off 6% http://t.co/XvEVmgAw
UPDATE 1-AstraZeneca CEO quits as earnings tumble | Reuters
reuters.com — “* David Brennan to retire early on June 1* CFO Simon Lowth to take over on interim basis* First-quarter earnings fall underscores pressure on groupBy Ben HirschlerLONDON, April 26 (Reuters) - AstraZeneca” View full resource at reuters.com
Most Recently Shared on April 26, 2012 at 6:53 am By:
Ben Hirschler Health Communicator
Today's big news - #AstraZeneca CEO quits as earnings tumble http://t.co/lkotFXzk via @reuters
AstraZeneca - AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
astrazeneca.com — “AstraZeneca - AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease” View full resource at astrazeneca.com
Most Recently Shared on April 25, 2012 at 4:45 pm By:
AZ & The Medicines Company announce global collaboration in acute ischaemic heart disease http://t.co/plWswd6t
Digital Pathology Blog: 3rd International Definiens Symposium to be held in Munich from June 14-16, 2012
tissuepathology.com — “Program features latest trends in quantitative digital pathology and tissue-based biomarker development with leading experts from Roche, AstraZeneca, Novartis and cutting-edge biomedical image and data analysis during hands-on workshops Munich, Germany, April 19, 2012 — Definiens®, the global leader of...” View full resource at tissuepathology.com
Most Recently Shared on April 24, 2012 at 3:46 am By:
tissuepathology Physician, Doctor, and Pathologist
3rd International Definiens Symposium to be held in Munich from June 14-16, 2012 http://t.co/aqMuj2jP
Advertisement
